Welcome, Guest
Username: Password: Remember me
The Company
  • Page:
  • 1

TOPIC: Presentation of Preclinical Data at ABA- May 5th

Presentation of Preclinical Data at ABA- May 5th 14 Apr 2016 06:04 #6820

  • fas
  • fas's Avatar Topic Author
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3356
  • Thank you received: 1116
Cytori Therapeutics to Present Preliminary Safety and Efficacy Preclinical Data at the 2016 American Burn Association Meeting

04/14/2016
SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that data from preclinical studies showing potential for Cytori’s DCCT-10 cell therapy product in the treatment of hypertrophic scarring (HTS), a common consequence of burn injury, will be presented at the Annual Meeting of the American Burn Association (ABA) in Las Vegas on May 5, 2016.

This research is a continuation of Cytori’s ongoing contract with the Biomedical Advanced Research and Development Authority (BARDA). As part of this work Cytori has developed a reproducible model possessing several of the characteristics of the HTS that occurs in humans following burn injury. In one study this model was applied to assess the ability of DCCT-10 treatment delivered immediately following initial burn surgery to impact the development of HTS. In a second study the same model was applied to assess use of DCCT-10 delivered six months after deep partial thickness injury in which a hypertrophic scar had already formed. The Cytori presentation will include early data indicating a potential beneficial effect of DCCT-10 in both processes. This research is an extension of earlier work that reported data suggesting that use of DCCT-10 was associated with improvement in several parameters associated with healing following thermal burn injury.

Hypertrophic scars are areas of hard, raised, red or purple scar tissue that often form at the site of burn injury. They are frequently hypersensitive and itchy. When present at or near a joint they can form contractures that reduce range of motion. In the absence of adequate non-surgical treatment options, the most effective approach has been to attempt to prevent or limit the formation of these scars by post-surgical use of pressure garments, steroid injections, and silicone sheets. Surgical intervention is often used to release contracture.

The following user(s) said Thank You: fatboy

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:
  • Page:
  • 1
Time to create page: 0.059 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites